News and Trends 12 Dec 2022OSE Immunotherapeutics announces latest acute lymphoblastic leukemia data OSE Immunotherapeutics SA has presented the latest preclinical data on the use of its anti-IL-7 receptor (IL-7R) antagonist OSE-127 for… December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published OSE Immunotherapeutics SA has announced the publication of data in the peer-reviewed journal Science Advances on a first-in-class preclinical program… November 23, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the… November 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 6 Jul 2020How Immuno-Oncology Contributes to the Fight Against Covid-19 As the Covid-19 pandemic sweeps the world, cancer research is proving a valuable resource for developing new treatments for infectious… July 6, 2020 - 7 minutesmins - By Maya Chergova Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2020French Partnership Deploys AI for Antibody Drug Discovery French companies OSE Immunotherapeutics and MAbSilico are teaming up to drive the discovery of new antibody drugs using artificial intelligence.… February 13, 2020 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 May 2019The Top 20 Women in Leading Biotech Roles in Europe The biotech industry has often been criticized for its lack of gender diversity. While there is still a long way… May 21, 2019 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2019Artificial Intelligence Could Beat Tumors Resistant to Immunotherapy The French company OSE Immunotherapeutics has signed a partnership to use artificial intelligence to develop treatments for tumors that don’t… March 27, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2018Boehringer Offers €1Bn for New Checkpoint Inhibitor from a French Biotech OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has set its eyes on a… April 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Mar 2018Say Hello to the Top 14 Entrepreneurial Women in European Biotech Today, March 8, is international women's day. To celebrate the achievements of women we're revisiting our list of the women… March 8, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2017Immunotherapy for Bowel Disease Gets €2.6M Milestone Payment from Bpifrance OSE Immunotherapeutics has successfully completed the necessary milestones to bring a treatment for autoimmune disease to the clinic, triggering a… June 22, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2017French Biotech Enters New Agreement to Advance its IBD Immunotherapy OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the development of its IL-7 antagonist… May 24, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2016Catching Up with the French Leader in Immuno-Oncology #BIOEurope Despite the deflating attitudes towards immuno-oncology, OSE Immunotherapeutics is forging ahead. We caught up with the CEO, Dominique Costantini, at… November 7, 2016 - 1 minutemin - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 25 Mar 2016Biotech of the Week: OSE Pharma, the ‘Significant’ Immunotherapy Player from Paris This week, we head up full speed from Geneva with our eyes aiming towards Paris. Known for its beauty, bohemian lifestyle… March 25, 2016 - 2 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2016French Biotech Launches Phase III Global Trial for Lung Cancer Drug OSE Pharma (France) has initiated the US phase III trial, Atalante 1. This global, pivotal trial will evaluate Tedopi, the company’s lead… February 8, 2016 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 20163 French Bioentrepreneurs are Awarded for Being Stubborn Building a company is extremely difficult and obstination is sometimes needed to reach success. The organisation, France Biotech, has given… January 7, 2016 - 3 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2016How these Latest Trials Prove PD-L1 as The Breakthrough Trend in Immuno-Oncology that is Here to Stay… By targeting platinum resistant Ovarian cancer, Avelumab is a new anti-PD-L1 checkpoint inhibitor on the Cancer block. This just affirms… January 5, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 17 Sep 2015France’s leading Female Bio-entrepreneur joins board of Abivax Dominique Costantini is one of France's leading biotech figures, with over 20 years experience on boards, partnerships and business backing… September 17, 2015 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 9 Sep 2015Encouraging results from Tedopi Phase II trials in patients with brain metastases French Immuno-oncology Biotech OSE Pharma has announced its phase II results for Tedopi trials showing outcome for patients with brain… September 9, 2015 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 19 Aug 2015Paris is Europe’s biggest Biocluster, but nobody knows it … Paris is well-known for being the most beautiful city in the world. But did you also know that it concentrates… August 19, 2015 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2015OSE Pharma raised €21.1 Million OSE Pharma’s Initial Public Offering couldn’t have been more successful as it just raised €21.1M. Noticing the strong demand for… March 27, 2015 - 1 minutemin - By Lourdes Riquelme Share WhatsApp Twitter Linkedin Email